Share ownership Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 14/01/2026 pm IST			5-day change	1st Jan Change
2,251.00 ^DKK	+4.89%		+6.38%	+11.05%

14/01	Genmab A/S Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 03:45 PM
08/01	UBS Raises Price Target for Genmab to 2,750 Danish Kroner (from 2,700), Reiterates Buy	FW

Share class: Genmab A/S

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,61,87,186	6,34,98,948 ( 95.94 %)	26,47,007 ( 3.999 %)	95.94 %

Major shareholders: Genmab A/S

Name	Equities	%	Valuation
GENMAB A/S 4.128 %	26,51,727	4.128 %	846 M kr
Orbis Investment Management Ltd. 4.08 %	26,20,635	4.08 %	836 M kr
Jan van de Winkel 0.9816 %	6,30,588	0.9816 %	201 M kr
Nykredit Bank A/S (Investment Management) 0.5219 %	3,35,280	0.5219 %	107 M kr
AllianceBernstein Investments Taiwan Ltd. 0.4659 %	2,99,280	0.4659 %	96 M kr
Robert W. Baird & Co., Inc. (Equity) 0.3184 %	2,04,509	0.3184 %	65 M kr
Sjunde AP-fonden 0.1501 %	96,412	0.1501 %	31 M kr
State Street Global Advisors Ltd. 0.1404 %	90,170	0.1404 %	29 M kr
Candriam SCA 0.1114 %	71,530	0.1114 %	23 M kr
Arca Fondi SGR SpA 0.1104 %	70,916	0.1104 %	23 M kr
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Orbis Investment Management Ltd. 1.725 %	1,10,78,006	1.725 %	341 M kr
AllianceBernstein LP 1.705 %	1,09,53,913	1.705 %	337 M kr
Paradigm BioCapital Advisors LP 0.5942 %	38,16,851	0.5942 %	118 M kr
Arrowstreet Capital LP 0.5671 %	36,43,139	0.5671 %	112 M kr
Harding Loevner LP 0.5424 %	34,84,487	0.5424 %	107 M kr
Aperio Group LLC 0.5155 %	33,11,449	0.5155 %	102 M kr
Renaissance Technologies LLC 0.4392 %	28,21,543	0.4392 %	87 M kr
First Trust Advisors LP 0.2627 %	16,87,388	0.2627 %	52 M kr
Eaton Vance Management 0.2607 %	16,74,574	0.2607 %	52 M kr
Two Sigma Advisers LP 0.223 %	14,32,800	0.223 %	44 M kr
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	101.61%
Other	5.08%
Genmab A/S	4.13%
Individuals	1.06%
SEI Investments Co.	0.11%
Fifth Third Bancorp	0.06%
Regions Financial Corp.	0.02%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	78.37%
Bermuda	21.32%
Denmark	4.82%
United Kingdom	2.23%
Individuals	1.06%
Canada	0.75%
Norway	0.54%
Taiwan	0.47%
Switzerland	0.35%
Ireland	0.34%
France	0.31%
Luxembourg	0.26%
Sweden	0.25%
Finland	0.2%
Italy	0.18%
Germany	0.17%
Australia	0.17%
Belgium	0.05%
Cayman Islands	0.05%
Austria	0.04%
Hong Kong	0.04%
Portugal	0.02%
Japan	0.02%
Mexico	0.01%
Spain	0.01%
Slovenia	0.01%
South Africa	0.01%
China	0.01%
Singapore	0.01%

Based on 1000 largest holdings

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (80.6%); - income from research and development (9.3%); - other (10.1%): primarily income from partnership agreement. At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).

Employees

2,681

Sector

Biotechnology & Medical Research

Calendar

05/02 - Q4 2025 Earnings Release

More about the company